stockrow
Saturday 7 November 2026
Export SLXN’s income statement to Excel — free account
Silexion Therapeutics Corp
SLXN Healthcare Biotechnology
- EPS
- +88.0%
- Free cash flow
- −16.6%
- Total debt
- −47.0%
Quarter to June 2026, against a year earlier
0.14
0.00
0.00%
Follow SLXN
Alert me
Silexion Therapeutics Corp (SLXN) P/E ratio
Silexion Therapeutics Corp has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 59.1× (March 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 59.1×
Ten-year median
0.0×
Current reading's percentile
85
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BRTX Biorestorative Therapies, Inc. compare | n/m |
| SILO Silo Pharma, Inc. compare | n/m |
| VIVS VivoSim Labs, Inc. compare | n/m |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| WINT Windtree Therapeutics, Inc. compare | n/m |
| HCWB HCW Biologics Inc. compare | n/m |
| APVO Aptevo Therapeutics Inc. compare | n/m |
| SLXN Silexion Therapeutics Corp | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)